Essential Polymyositis pipeline therapies such as ... intended to be a novel treatment for autoimmune diseases where the pathology is driven principally by overproduction of type I interferons ...

polymyositis and inclusion body myositis, according to differences in clinical and histopathological features. The muscle pathology shows characteristic inflammatory exudates of variable ...

“C-protein-induced myositis [CIM] is much more like human polymyositis in pathology than previous models, including the commonly used experimental autoimmune myositis, which is induced with ...

Belonging to the same group of autoimmune diseases, both dermatomyositis and polymyositis cause muscle inflammation and weakness. But dermatomyositis also affects your skin and is more likely to ...

“Similar to our phase 1/2 trial design in SLE, this clinical trial will include patients with several different subtypes of myositis where B cells may be involved in disease pathology ...

Myositis is a condition that causes inflammation of the muscles. There are different types of myositis, which may be the result of an infection, injury, medication, or autoimmune disease. Read on ...

“We are very pleased to have received orphan drug designations for both polymyositis and dermatomyositis. This recognition spotlights the significant unmet need for patients living with these ...

Polymyositis (PM) and dermatomyositis (DM) may involve the striated muscle of the esophagus, leading to abnormal swallowing that in turn can lead to malnutrition and/or aspiration. Esophageal ...

PF1801 is a novel long-acting glucagon-like peptide-1 receptor agonist. The Food and Drug Administration (FDA) has granted Orphan Drug designation to PF1801 for the treatment of polymyositis.

New research is painting a more distinct picture of necrotizing autoimmune myopathy (NAM), a subcategory of acquired idiopathic myopathies characterized by subacute proximal limb muscle weakness ...